Sir, We read with great interest the review by Mahajan et al. [1] regarding an update on pityriasis rosea (PR) recently published on your journal. The article prompted us, on the basis of our experience, to make some observations. Controversial opinion remains on PR seasonal prevalence mainly related to its occurrence in clusters. Chuh et al. [2] who examined patients from three different geographic areas found significant clustering though in different seasons. In our experience on 590 patients, PR occurs uniformly all during the year, and we could not demonstrate statistically significant cluster. [3] The authors make also an exhaustive description of all the morphological variants of PR and its recurrent form, but not cite the most recent classification of all PR variants. [4] This classification is easy and intuitive for dermatologists, general practitioners, and other specialists taking simultaneously into account the pathogenesis, clinical features, and course of the disease. In addition, it may be helpful in identifying the atypical forms of PR to avoid misdiagnosis and establish the best treatment options. Finally, this classification provides indications for managing potentially harmful forms of PR (such as PR in pregnancy) and PR-like eruptions. In fact, in case of PR during pregnancy, a particular attention should be carried out when PR develops within the 15 th gestational week and is associated with an aggressive course with unusually widespread skin lesions, long duration, and severe constitutional symptoms. In these cases, a prolonged human herpesvirus 6 viral reactivation in the plasma may facilitate intrauterine transmission with fetal damage. Notably, these data are obtained by a careful follow-up from 61 women who developed PR during pregnancy, using the most modern techniques of molecular biology. [4] Other studies on PR during pregnancy are partial and cover a few cases little more than anecdotal. Finally, we believe to be important to report the criteria recently proposed for distinguishing between PR and PR-like eruptions [5] and vaccine-induced PR and PR-like eruptions [6] since they have a completely different pathogenesis from a virological point of view.
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Sir, We are grateful to the authors for such a comprehensive reading of our article and making enlightening observations regarding the same. [1] As already pointed out, clustering and seasonal variation remains a controversial point in pityriasis rosea (PR) as different studies have conflicting observations and so a definite opinion cannot be drawn.
The recent classification of PR variants by Drago et al.
is indeed the most comprehensive classification available till date and provides the most elaborate and exhaustive view on most commonly seen clinical variants with ready to take away points which will help differentiate between different manifestations of PR. However, since this classification was published at a later stage than our article, the same could not be incorporated in our review article.
PR being a very common condition with evolving pathogenesis, varied presentations, and therapeutic options; there are a lot of studies and review articles already published or underway dealing with different aspects of it. Thus, with the limitations of word limit, despite an extensive literature search, not all of it could be incorporated under one review article. The aim of our review was to cover all important headings with special emphasis on etiopathogenesis and management of difficult aspects, which had so far being not dealt with in detail.
The articles cited are definitely a useful source of further and more elaborate information, and we recommend their reading in special cases as in when dealing with vaccine induced and PR-like eruptions. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
